Anaptysbio (ANAB) Free Cash Flow (2016 - 2026)
Anaptysbio's (ANAB) quarterly Free Cash Flow came in at -$25.9 million in Q1 2026, down 142.14% YoY from $61.5 million in Q1 2025, and down 126.49% on a QoQ basis from $97.9 million in Q4 2025.
Anaptysbio (ANAB) Free Cash Flow (2016 - 2026) Analysis & Trends
Anaptysbio (ANAB) has 11 years of Free Cash Flow data on file, last reported at -$25.9 million in Q1 2026.
- Quarterly Free Cash Flow fell 142.14% year-over-year to -$25.9 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $4.4 million (up 104.03% YoY) and the FY2025 annual result came in at $19.6 million, up 114.49% from the prior year.
- Free Cash Flow fell to -$25.9 million in Q1 2026, from $97.9 million in the prior quarter.
- In the past five years, Free Cash Flow ranged from a high of $97.9 million in Q4 2025 to a low of -$66.7 million in Q4 2024.
- A 5-year average of -$19.8 million and a median of -$24.7 million in 2023 frame the typical range for Free Cash Flow.
- Annual changes were most pronounced in 2022 — Free Cash Flow slumped 376.03% — and 2025, when it soared 246.85%.
- Tracing ANAB's Free Cash Flow over 5 years: stood at -$10.8 million in 2022, then slumped by 220.31% to -$34.6 million in 2023, then tumbled by 92.54% to -$66.7 million in 2024, then soared by 246.85% to $97.9 million in 2025, then slumped by 126.49% to -$25.9 million in 2026.
- The last three Free Cash Flow figures came in at -$25.9 million (Q1 2026), $97.9 million (Q4 2025), and -$27.3 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Free Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.01 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 572.80 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -389.61 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 437.80 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -2.33 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 477.44 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 292.04 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -95.09 Mn |
| 10 | Anaptysbio | 1.70 Bn | 1.41 Bn | - | -25.94 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -25.94 Mn |
| Mar 31, 2026 | -25.94 Mn |
| Dec 31, 2025 | 97.91 Mn |
| Dec 31, 2025 | 97.91 Mn |
| Sep 30, 2025 | -27.28 Mn |
| Sep 30, 2025 | -27.28 Mn |
| Jun 30, 2025 | -40.31 Mn |
| Jun 30, 2025 | -40.31 Mn |
| Mar 31, 2025 | -10.71 Mn |
| Mar 31, 2025 | -10.71 Mn |
| Dec 31, 2024 | -66.68 Mn |
| Dec 31, 2024 | -66.68 Mn |
| Sep 30, 2024 | -10.03 Mn |
| Sep 30, 2024 | -10.03 Mn |
| Jun 30, 2024 | -21.36 Mn |
| Jun 30, 2024 | -21.36 Mn |
| Mar 31, 2024 | -37.28 Mn |
| Mar 31, 2024 | -37.28 Mn |
| Dec 31, 2023 | -34.63 Mn |
| Dec 31, 2023 | -34.63 Mn |